News

FLAGSTAFF, Ariz. (March 11, 2021)— W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention.

FLAGSTAFF, Ariz. (November 18, 2020) — W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device. Six-month data for 16 patients enrolled across three sites in the United States were presented in a moderated poster session during the American Heart Association Virtual Scientific Sessions from November 13-17, 2020. The poster, P148, is titled, Early Results of a Novel ePTFE-based Pulmonary Valved Conduit in a Pediatric Patient Population.

FLAGSTAFF, Ariz – September 22, 2020 – As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the U.S. launch of the lower profile, large diameter GORE® VIABAHN® Endoprosthesis.

FLAGSTAFF, Ariz. (August 25, 2020) — W. L. Gore & Associates is marking the 20th anniversary of the only covered stent indicated for transjugular intrahepatic portosystemic shunt procedures (TIPS). The GORE^® VIATORR^® TIPS Endoprosthesis, marketed since 2000, and GORE^® VIATORR^® TIPS Endoprosthesis with Controlled Expansion, introduced in 2016, have helped physicians in more than 60 countries to increase survival and improve quality of life in high-risk bleeding and refractory ascites patients.

As the world moves forward shaped by the COVID-19 pandemic, so many of us crave a “return to normal.” At Gore, we too are eager for our Associates to rejoin their colleagues who have remained in our plants to produce essential materials and products.

W. L. Gore & Associates, Inc. (Gore) congratulates the REVISE research team for receiving the JVIR Editor’s Award for Outstanding Clinical Research Paper for 2019 from the Journal of Vascular and Interventional Radiology.

FLAGSTAFF, Ariz. (December 11, 2013) — W. L. Gore & Associates (Gore) today announced that the Food and Drug Administration (FDA) has granted indication for the GORE® VIABAHN® Endoprosthesis to treat stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous access (AV access) grafts.